Ren-Pin Chen

Ren-Pin Chen

Auto-generated profile, based on publicly available information

Ren-Pin Chen

Sinosteel Luoyang Institute of Refractories Research Co., Ltd

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
WXWei Xie
Wei Xie
XHXielin Huang
Xielin Huang
RCRenpin Chen
Renpin Chen
RCRuru Chen
Ruru Chen
TLTang Li
Tang Li
ZHZhiming Huang
Zhiming Huang
Background: Stress ulcer is a severe complication in critically ill patients and causes a high mortality. The proton pump inhibitor esomeprazole is widely applied in the treatment of stress ulcers because of its powerful acid suppression ability. However, the mechanism of stress ulcer and the precise gastroprotective effect of esomeprazole in stress ulcer remain unclear. Purpose: In the present study, the rats with water-immersed and restraint (WIR)-induced stress ulcer were used to further elucidate the anti-ulcerogenic capacity of esomeprazole in stress ulcer in addition to its anti-acid secreting ability. Methods and results: The rats were randomly divided into 5 groups: control group (NS), water-immersed and restraint group (WIR), high-dose application of esomeprazole plus stress ulcer-induced group (HE+WIR), low-dose application of esomeprazole plus stress ulcer-induced group (LE+WIR), and high-dose application of esomeprazole without stress ulcer-induced group (HE). Our study showed that the pretreatment of esomeprazole alleviated gastric tissue damage in both macroscopic and histopathological manifestations. Pretreatment of esomeprazole elevated the decline in PEG2 level affected by WIR; and it inhibited the secretion of gastric acid, gastrin and pepsin. Moreover, esomeprazole exerted its antioxidant effects by reducing malondialdehyde levels, enhancing the expressions of antioxidant factors like glutathione and superoxide dismutase (SOD) and reducing the compensatory transcriptional elevation of SOD1 gene. Esomeprazole also reduced the levels of MPO (myeloperoxidase), tumor necrosis factor (TNF)-α and interleukin (IL)-1β according to its anti-inflammatory effects. We further explored the possible mechanism of esomeprazole pretreatment on stress ulcer and demonstrated that esomeprazole attenuated the high phosphorylation levels of nuclear factor kappa B (NF-κB) p65 and p38 MAPK, and decreased the NF-κB p65 nuclear translocation induced by WIR related stress ulcer. Conclusion: Our study provides some evidence that the esomeprazole pretreatment exerts gastroprotective effects in WIR-induced stress ulcer through not only its antisecretory effect but also its antioxidant effect by inactivating the p38 MAPK and NF-κB signaling pathways.

1 January 2016 in Gastroenterology Research and Practice
Verified
Journal Article
Open access
PDF file
XWXiao-Li Wu
Xiao-Li Wu
RCRen-Pin Chen
Ren-Pin Chen
LTLi-Ping Tao
Li-Ping Tao
JWJian-Sheng Wu
Jian-Sheng Wu
XCXiang-Rong Chen
Xiang-Rong Chen
WCWeichang Chen
Weichang Chen
Aim. This study was performed to evaluate the additional enteral nutrition (EN) in the efficacy of infliximab (IFX) compared with the conventional therapy in managing Crohn’s disease (CD) complicated with intestinal fistulas.Methods. A total of 42 CD with intestinal fistulas were randomly divided into infliximab treatment group (n=20) and conventional therapy group (n=22). We evaluated the laboratory indexes, Crohn’s disease activity index (CDAI), Crohn’s disease simplified endoscopic score (SES-CD), and healing of fistula in the two groups before treatment, at 14 weeks, and at 30 weeks, respectively.Results. In the IFX treatment group, the CDAI score, the SES-CD, erythrocyte sedimentation rate, and C-reactive protein levels were significantly decreased during treatment compared with those before treatment. The body mass index and albumin levels were increased in both groups. Moreover, in the IFX treatment group, fistula healing was found in 8 at the 14th week and 18 at the 30th week, respectively, which was greater than that in the conventional therapy group.Conclusion. Our study suggested that infliximab combined with EN is an effective treatment for CD patients complicated with intestinal fistulas.

28 March 2012 in Hepatogastroenterology
Verified
Journal Article
Closed access
TCTanzhou Chen
Tanzhou Chen
XYXiaohua Ye
Xiaohua Ye
ZHZhiming Huang
Zhiming Huang
RCRenpin Chen
Renpin Chen
XZXiaoju Zhuge
Xiaoju Zhuge
YDYong Du
Yong Du
Severe acute pancreatitis (SAP)-associated liver injury is systematically one of main pathophysiological events due to SAP development. The aim of the study was to investigate whether fgl2 prothrombinase is involved in SAP-associated liver injury. Microthrombosis in the liver of rats with SAP was observed by Masson staining. Fgl2 prothrombinase expression in the liver of rats with SAP was analyzed by real-time PCR and immunohistochemistry methods. Fgl2 prothrombinase gene and protein expression in SAP group were significantly up-regulated compared to sham-operation (SO) group. Immunohistochemistry staining showed that fgl2 prothrombinase was localized speci?cally to the endothelial cells of intrahepatic veins and hepatic sinusoids. Furthermore, Masson staining demonstrated that the proportion of hepatic microthrombotic capillaries in SAP group were evidently increasing in comparison to SO group and closely correlated with fgl2 expression (r=0.948, p<0.01 ). In addition, there was a positive correlation between fgl2 expression and the severity of hepatocellular injury as indicated by hepatic pathological grade (r=0.704, p<0.01). Fgl2 prothrombinase may contribute to microthrombosis in SAP-associated liver injury, thus resulting in hepatic microcirculatory disturbance and measurement of fgl2 may be used as a helpful biomarker in the prognosis of the severity of hepatic pathological injury in SAP.

28 February 2014 in Hepatology
Verified
Journal Article
Open access
PDF file
RCRen-Pin Chen
Ren-Pin Chen
Chao ChenChao Chen
Chao Chen
JYJie-Yu Yu
Jie-Yu Yu
XHXie-Lin Huang
Xie-Lin Huang
MZMeng-Tao Zhou
Meng-Tao Zhou
ZHZhi-Ming Huang
Zhi-Ming Huang
Click on the article title to read more.

25 September 2022
Verified
Book Chapter
Closed access
PDF file
CRChen Renpin
Chen Renpin
SGShi Gan
Shi Gan
XKXu Kuangdi
Xu Kuangdi